Key Takeaways
- CVS delivered adjusted earnings of $2.57 per share, surpassing Wall Street’s $2.18 projection for the fifth quarter in a row
- Quarterly revenue reached $100.4 billion, significantly exceeding analyst forecasts of $95 billion
- Aetna’s medical benefit ratio dropped to 84.6% from 87.3% in the prior-year period
- Company increased 2026 adjusted EPS outlook to $7.30–$7.50, above previous range of $7.00–$7.20
- Shares rose 4.9% in premarket activity following the earnings announcement
CVS Health shares surged 4.9% during premarket hours Wednesday following a robust first-quarter performance and an upward revision to annual forecasts.
The healthcare giant reported adjusted earnings of $2.57 per share, topping the $2.18 consensus estimate from analysts. Quarterly revenue of $100.4 billion similarly exceeded Wall Street’s $95 billion projection.
This represents the fifth consecutive quarter where CVS has beaten earnings expectations. Management has maintained conservative guidance while navigating a comprehensive operational overhaul following challenges experienced throughout 2024.
CVS elevated its 2026 adjusted earnings per share forecast to between $7.30 and $7.50, compared to the prior range of $7.00 to $7.20. The company simultaneously boosted its operating cash flow projection to a minimum of $9.5 billion, up from at least $9 billion previously.
Prior to Wednesday’s session, the stock had advanced only 1.7% in 2025, underperforming the S&P 500’s 6% gain over the same timeframe.
Aetna Insurance Unit Shows Cost Management Success
The most impressive metric emerged from the medical benefit ratio within CVS’s Aetna insurance division. The ratio registered 84.6%, substantially below analyst expectations of 87.58% and marking improvement from last year’s 87.3%.
This ratio tracks the percentage of premium income allocated to medical expenses. A declining figure indicates greater profitability for the insurer. CFO Brian Newman attributed the progress to enhanced forecasting capabilities and tighter expense management.
Both UnitedHealth and Humana similarly exceeded projections on this measure during Q1, suggesting widespread gains among Medicare Advantage providers.
The federal government announced in April a 2.48% average increase to 2027 Medicare Advantage reimbursement rates. Newman noted this raise remains insufficient relative to anticipated cost growth next year, potentially requiring CVS to modify pricing structures or benefit offerings.
Pharmacy Benefit Manager Grows While Retail Operations Face Headwinds
CVS’s health services division, encompassing the Caremark pharmacy benefit manager, reported an 11% revenue jump to $48.2 billion. The segment generated $1.34 billion in operating income, matching analyst projections.
Newman pointed to a more profitable pharmaceutical mix as the driver behind Caremark’s performance. Leerink analyst Michael Cherny had previously identified reaching $1.3 billion in adjusted operating income for this segment as critical for rebuilding investor trust.
Pharmacy benefit managers continue facing scrutiny from legislators and regulatory bodies regarding drug pricing mechanisms. CVS currently has an unresolved FTC settlement concerning accusations that its PBM drove up insulin costs, claims the company disputes.
The company is also challenging a Tennessee legislative proposal that would prohibit PBMs from operating pharmacies within state borders. The measure has cleared the state legislature and awaits gubernatorial review.
The retail pharmacy division experienced 5% revenue growth in 2025 following the integration of Rite Aid locations, which brought 9 million additional customers. However, operating income for this unit declined 8.8% year-over-year during Q1.
CVS attributed the pharmacy segment’s profit decline to regulatory modifications affecting specific medication pricing, reduced cold and flu season activity, and weather-related disruptions — including temporary closures from winter storms.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
